Belite Bio (BLTE) CSO gains 144,868-share option vesting

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata had additional stock options vest tied to performance goals. An existing option grant from April 18, 2022 vested as to 144,868 ordinary shares on March 31, 2026 after a performance criterion was met.

The vested option covers ordinary shares at an exercise price of $6.00 per share and now totals 267,934 exercisable shares, including 123,066 shares that had previously vested. This is a compensation-related award, not an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MATA NATHAN L.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	144,868	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 267,934 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Newly vested options: 144,868 shares Exercise price: $6.00 per share Total exercisable options: 267,934 shares +3 more

6 metrics

Newly vested options 144,868 shares Portion of April 18, 2022 grant vesting on March 31, 2026

Exercise price $6.00 per share Stock option exercise price for ordinary shares

Total exercisable options 267,934 shares Options exercisable following March 31, 2026 vesting

Previously vested options 123,066 shares Ordinary shares under the option that had already vested

Option expiration date April 17, 2032 Scheduled expiration of the stock option grant

Grant date April 18, 2022 Original date the stock option was granted

Key Terms

Stock Option (right to buy), performance criteria, vested, exercise price, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

performance criteria financial

"shall vest in installments upon satisfaction of certain performance criteria"

vested financial

"123,066 ordinary shares subject to the option that had previously vested remain exercisable"

exercise price financial

"conversion_or_exercise_price: 6.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2032-04-17T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last) (First) (Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6	03/31/2026		A		144,868		03/31/2026	04/17/2032	Ordinary Shares	144,868	$0	267,934(1)	D

Explanation of Responses:

1. On April 18, 2022, the reporting person was granted an option which shall vest in installments upon satisfaction of certain performance criteria. 123,066 ordinary shares subject to the option that had previously vested remain exercisable. One of the performance criteria was met on 3/31/2026, resulting in vesting of the option as to additional 144,868 ordinary shares.

	/s/ NATHAN L. MATA	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) report for Nathan L. Mata?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata had additional stock options vest on March 31, 2026. An existing option grant from April 18, 2022 vested as to 144,868 ordinary shares after a specified performance criterion was achieved.

How many Belite Bio stock options are now exercisable by Nathan L. Mata?

After the latest vesting, Nathan L. Mata has 267,934 ordinary shares subject to stock options exercisable. This total includes 123,066 shares that had previously vested and an additional 144,868 shares that vested when performance criteria were satisfied.

What are the key terms of Nathan L. Mata’s Belite Bio stock option?

The option gives Nathan L. Mata the right to buy 144,868 ordinary shares at an exercise price of $6.00 per share. It was originally granted on April 18, 2022 and is scheduled to expire on April 17, 2032, subject to its standard terms.

Was there any open-market buying or selling of Belite Bio shares in this Form 4?

No open-market buying or selling occurred in this filing. The Form 4 reflects vesting of a previously granted stock option at $0.00 transaction price per share, giving the right to purchase shares at a $6.00 exercise price instead of an immediate market trade.

What triggered the latest vesting of Belite Bio options for Nathan L. Mata?

The latest vesting was triggered when one of the performance criteria attached to the April 18, 2022 option grant was met on March 31, 2026. That milestone caused 144,868 additional ordinary shares under the option to become vested and exercisable.